Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with […]readmore
Tags : Shire
Regulatory
Shire’s Motegrity (prucalopride) Receives FDA Approval for Chronic Idiopathic Constipation
Shots: The approval is based on six trials assessing Motegrity vs PBO in 2,484 patients with Chronic Idiopathic Constipation (CIC) in adults P-III study results: normalization of BM frequency (19-38% […]readmore
Shots: The approval is based on P-III HELP study results assessing Takhzyro (300 mg q2w, 300 mg q4w, 150 mg q4w) vs PBO in 125 patients with HAE aged ≥12 […]readmore
Shots: Approval is based on three clinical trials (N=80) assessing safety, tolerability, PK, haemostatic efficacy of rVWF in adults: P-III for rFVIII with severe VWD; P-III for rFVIII and rVWF […]readmore
Shots: This acquisition is expected to increase continued access for Shire in plasma collection network advancing its facilities of supply and manufacturing units Shire will take over Sanaplasma AG’s 14 […]readmore
Shots: Approval is based on four clinical studies including P-III HELP (Hereditary Angioedema Long-term Prophylaxis) study (N=125) for 26 wks, administering Takhzyro 300mg Q2W, Q4W and 150 mg Q4W HELP […]readmore